Switch theme
Sign up to access all valuation multiples
Walvax Biotechnology Co Ltd is engaged in research and development, production and sales of vaccine products.
2001
2.4K+
LTM Revenue $396M
LTM EBITDA $90.7M
$2.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Walvax Biotechnology has a last 12-month revenue (LTM) of $396M and a last 12-month EBITDA of $90.7M.
In the most recent fiscal year, Walvax Biotechnology achieved revenue of $394M and an EBITDA of $80.9M.
Walvax Biotechnology expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Walvax Biotechnology valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $396M | XXX | $394M | XXX | XXX | XXX |
| Gross Profit | $315M | XXX | $314M | XXX | XXX | XXX |
| Gross Margin | 80% | XXX | 80% | XXX | XXX | XXX |
| EBITDA | $90.7M | XXX | $80.9M | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 21% | XXX | XXX | XXX |
| EBIT | $51.4M | XXX | $40.7M | XXX | XXX | XXX |
| EBIT Margin | 13% | XXX | 10% | XXX | XXX | XXX |
| Net Profit | $32.6M | XXX | $19.8M | XXX | XXX | XXX |
| Net Margin | 8% | XXX | 5% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 16, 2025, Walvax Biotechnology's stock price is CNY 11 (or $2).
Walvax Biotechnology has current market cap of CNY 18.1B (or $2.5B), and EV of CNY 15.0B (or $2.1B).
See Walvax Biotechnology trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.1B | $2.5B | XXX | XXX | XXX | XXX | $0.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 16, 2025, Walvax Biotechnology has market cap of $2.5B and EV of $2.1B.
Walvax Biotechnology's trades at 5.3x EV/Revenue multiple, and 25.9x EV/EBITDA.
Equity research analysts estimate Walvax Biotechnology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Walvax Biotechnology has a P/E ratio of 77.5x.
See valuation multiples for Walvax Biotechnology and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.5B | XXX | $2.5B | XXX | XXX | XXX |
| EV (current) | $2.1B | XXX | $2.1B | XXX | XXX | XXX |
| EV/Revenue | 5.3x | XXX | 5.3x | XXX | XXX | XXX |
| EV/EBITDA | 23.1x | XXX | 25.9x | XXX | XXX | XXX |
| EV/EBIT | 40.8x | XXX | 51.5x | XXX | XXX | XXX |
| EV/Gross Profit | 6.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | 77.5x | XXX | 127.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 30.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialWalvax Biotechnology's last 12 month revenue growth is 6%
Walvax Biotechnology's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Walvax Biotechnology's rule of 40 is 28% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Walvax Biotechnology's rule of X is 38% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Walvax Biotechnology and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Growth | 32% | XXX | -6% | XXX | XXX | XXX |
| Rule of 40 | 28% | XXX | 27% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 38% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 33% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 21% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 69% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Walvax Biotechnology acquired XXX companies to date.
Last acquisition by Walvax Biotechnology was XXXXXXXX, XXXXX XXXXX XXXXXX . Walvax Biotechnology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Walvax Biotechnology founded? | Walvax Biotechnology was founded in 2001. |
| Where is Walvax Biotechnology headquartered? | Walvax Biotechnology is headquartered in China. |
| How many employees does Walvax Biotechnology have? | As of today, Walvax Biotechnology has 2.4K+ employees. |
| Is Walvax Biotechnology publicy listed? | Yes, Walvax Biotechnology is a public company listed on SHE. |
| What is the stock symbol of Walvax Biotechnology? | Walvax Biotechnology trades under 300142 ticker. |
| When did Walvax Biotechnology go public? | Walvax Biotechnology went public in 2011. |
| Who are competitors of Walvax Biotechnology? | Similar companies to Walvax Biotechnology include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of Walvax Biotechnology? | Walvax Biotechnology's current market cap is $2.5B |
| What is the current revenue of Walvax Biotechnology? | Walvax Biotechnology's last 12 months revenue is $396M. |
| What is the current revenue growth of Walvax Biotechnology? | Walvax Biotechnology revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Walvax Biotechnology? | Current revenue multiple of Walvax Biotechnology is 5.3x. |
| Is Walvax Biotechnology profitable? | Yes, Walvax Biotechnology is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Walvax Biotechnology? | Walvax Biotechnology's last 12 months EBITDA is $90.7M. |
| What is Walvax Biotechnology's EBITDA margin? | Walvax Biotechnology's last 12 months EBITDA margin is 23%. |
| What is the current EV/EBITDA multiple of Walvax Biotechnology? | Current EBITDA multiple of Walvax Biotechnology is 23.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
